Fe₃O₄@SiO₂-imid-PMAⁿ catalyzed synthesis of α -aminophosphonates.

A green one-pot three-component synthesis of α -aminophosphonates under solvent-free conditions and ultrasonic irradiation using Fe₃O₄@SiO₂-imid-PMAⁿ as magnetic catalyst

Mohsen Esmaeilpour^{*,a}, Saeed Zahmatkesh^{*,b}, Jaber Javidi^c, Elahe Rezaei^b

^aChemistry Department, College of Science, Shiraz University, Shiraz, Iran

^bDepartment of Science, Payame Noor University (PNU), 19395-4697, Tehran, Islamic Republic of Iran

^cDepartment of Pharmaceutics, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran

^{*}Corresponding author. Tel.: +98 7136137738, fax: +98 7132286008. E-mail address: E-mail address: m1250m551085@yahoo.com (M. Esmaeilpour), zahmatkesh1355@yahoo.com (S. Zahmatkesh)

Abstract

An efficient and environment friendly process for the synthesis of α -aminophosphonates has been devised. Through a one-pot three-component condensation of various aldehydes, amines, and triethyl phosphite in the presence of Fe₃O₄@SiO₂-imid-PMAⁿ nanoparticles as magnetic catalysts under solvent-free conditions and ultrasonic irradiation, α -aminophosphonates were obtained with excellent yields. The reactions under solvent-free conditions at room temperature are compared with the ultrasonic-assisted reactions. This new procedure has notable advantages such as short reaction time, excellent yields, easy purification, and absence of any tedious workup or purification. The aforementioned catalyst could be easily recovered by an external

¹ ACCEPTED MANUSCRIPT

magnetic field and can be reused for six consecutive reaction cycles without significant loss of activity. In addition, SEM and DLS of the catalyst after the reaction cycle were investigated. GRAPHICAL ABSTRACT



Keywords

α-Aminophosphonates; Multi-component reaction; One-pot synthesis; Solvent-free reaction; Green synthesis; Ultrasonic irradiation.

² ACCEPTED MANUSCRIPT

1. Introduction

 α -Aminophosphonates are structurally analogous to amino acids. They have been found to exhibit a pivotal role in synthetic organic chemistry as well as in medicinal chemistry.^[1,2] The medicinal importance and biological effects of α -aminophosphonate derivatives, such as antithrombotic agent,^[3] anticancer agent,^[4] antihypertensive agents,^[5] anti-inflammatory agent,^[6] catalytic antibodies,^[7] potential antioxidants,^[1] antibiotic,^[4] biotryticides^[8] enzyme inhibitors,^[9] carriers of hydrophilic organic molecules across phospholipid membranes,^[10] HIV protease,^[11] and peptidases and proteases^[12] have stimulated scientific research to develop many synthetic procedures for them. Also, they can be used as fungicides,^[13] herbicides,^[14] insecticides,^[15] plant virucides^[16] and hypothetical radio protecting agent.^[17] These methods include the use of Brønsted acids such as Amberlite-IR 120,^[18] sulfamic acid,^[19] hypophosphorus acid,^[20] CF_3CO_2H ,^[21] oxalic acid^[22] and Lewis acids such as Al(H₂PO₄)₃,^[23] Na₂CaP₂O₇,^[24] LiClO₄,^[25] SbCl₃/Al₂O₃,^[26] InCl₃,^[27] BiCl₃,^[28] ZrCl₄,^[29] FeCl₃,^[30] SiO₂@TaCl₅,^[31] TiO₂,^[32] Yb(PFO)₃^[33] (bromodimethyl)sulfonium bromide^[34] and trimethylanilinium chloride.^[35] However, many of the reported synthetic protocols for the synthesis of α -aminophosphonates suffer from one or more disadvantages such as using toxic, expensive and moisture sensitive catalysts, long reaction times, poor yields, harsh reaction conditions, tedious separation procedures and the use of heavy metal catalysts. Therefore, the development of a new catalytic system to overcome these shortcomings and fulfill the criteria of an effective, convenient, and green protocol for the synthesis of α -aminophosphonates is still a challenge.

In recent years, magnetite (Fe_3O_4) nanoparticles have attracted increasing interest due to the interesting properties including a low toxicity, superparamagnetism, biocompatibility, large

³ ACCEPTED MANUSCRIPT

surface to volume ratio and wide application range including magnetic resonance imaging, targeted gene therapy, magnetic data storage, drug delivery systems, biosensors, environmental remediation, ion exchange separation, magnetic bioseparations, treatment of cancer and catalysis.^[36-40] For many applications, magnetic nanoparticles are suitable because they are chemically stable and uniform in size. Nevertheless, magnetic nanoparticles easily aggregate because of anisotropic dipolar attraction and alter their magnetic properties. Therefore, a protection layer is important to avoid such limitations from occurring.^[41] For this purpose, silica has been widely used because of its stability under different reaction conditions and due to the fact that it can be easily functionalized for diverse applications.^[42] Recently, surface functionalized magnetic nanoparticles have been developed in a range of organic transformations, and the studies on immobilization of organo catalysts on core-shell nanoparticles have been reported.^[43-46]

In our previous study,^[47] $H_3PMo_{12}O_{40}$ nanoparticles were synthesized and these nanoheteropolyacids were immobilized onto the imidazole functionalized Fe₃O₄@SiO₂ nanoparticles. Compared to other substrates (silica, active carbon, nano-titania and acidic ion-exchange resins), Fe₃O₄@SiO₂-imid nanoparticles have various advantages such as low leaching, high loading capacity and simple and efficient recovery procedure. Fig. 1 presents the procedure for the stepwise preparation of Fe₃O₄@SiO₂-imid-PMAⁿ.

In the present research, we describe an efficient, facile, and convenient procedure for the synthesis of α -aminophosphonates by condensation of various aldehydes with amines and triethyl phosphite in the presence of Fe₃O₄@SiO₂-imid-PMAⁿ in a one-pot three-component synthesis under solvent-free conditions and ultrasonic irradiation at room temperature.

⁴ ACCEPTED MANUSCRIPT

2. Results and discussions

In our previous work,^[47] the Fe₃O₄, Fe₃O₄@SiO₂ and Fe₃O₄@SiO₂-imid-PMAⁿ nanocatalysts were characterized by various methods such as transmission electron microscopy (TEM), scanning electron microscopy (SEM), dynamic light scattering (DLS), Fourier transform infrared (FT-IR), vibrating sample magnetometer (VSM) etc. The presence of vibration bands at 556, 794, 864, 956,1055,1095, 1454 and 2792-2985 cm⁻¹ which is due to the Fe–O, Mo–O_e–MO, Mo–O_c–MO, Mo–O_t, P–O, Si–O–Si, C = N and CH bonds respectively, demonstrates the existence of Fe₃O₄@SiO₂-imid-PMAⁿ (Fig. 1).^[47] Fig. 1 shows the XRD pattern for Fe₃O₄@SiO₂-imid-PMAⁿ nanoparticles. For Fe₃O₄@SiO₂-imid-PMAⁿ nanoparticles, the presence of the silica and imid-PMAⁿ layers on the Fe₃O₄ nanoparticles, leads to an amorphous structure and the disappearance of peaks corresponding to Fe_3O_4 and PMA^{n} .^[47] The magnetic properties of nanoparticles were measured by VSM at room temperature. The saturation magnetization of Fe₃O₄, Fe₃O₄@SiO₂ and Fe₃O₄@SiO₂-imid-PMAⁿ is 63.4, 39.7, 33.2 emu/g, respectively.^[47] As shown in Fig. 1, Fe₃O₄@SiO₂-imid-PMAⁿ nanoparticles have spherical shapes with approximately 50 nm diameters. The size distribution of these is centered at a value of 55 nm.^[47]

In continuation of our research work of developing methods in various organic transformations, herein we describe $Fe_3O_4@SiO_2$ -imid-PMAⁿ as a heterogeneous acid catalyst for the synthesis of α -aminophosphonates in a one-pot reaction under solvent-free reaction conditions or ultrasonic irradiation at room temperature (Scheme 1).

Initially, we attempted the one pot coupling of benzaldehyde (1 mmol), aniline (1 mmol), and triethyl phosphite (1.2 mmol) as the model reaction to optimize the reaction conditions. First, we

⁵ ACCEPTED MANUSCRIPT

examined the reaction in the presence of varying amounts of the catalyst. The results are presented in Table 1. The best result was achieved by carrying out the reaction with a (0.015 g: 1 mmol: 1 mmol: 1.2 mmol) ratio of $Fe_3O_4@SiO_2$ -imid-PMAⁿ catalyst, benzaldehyde, aniline and triethyl phosphite under solvent free conditions at room temperature (Table 1, entry 4). Use of a higher amount of the catalyst did not improve the yield (Table 1, entry 5) while a decrease of the amount of catalyst resulted in lower yields under the same conditions (Table 1, entries 2, 3). The results show clearly that the catalyst is effective for this transformation. In the absence of the catalyst the reaction did not take place even after longer reaction times (Table 1, entry 1).

Then, we conducted the reactions in CH_2Cl_2 , $CHCl_3$, CH_3CN , THF, Et_2O , EtOH, C_2H_5OH/H_2O and H_2O as solvents and under solventless conditions (Table 1, entries 4 and 6-13). The presented data in Table 1 show that the reaction proceeded efficiently under solvent-free conditions and resulted in high yields of the desired product (Table 1, entry 4).

To investigate the ability of ultrasonic irradiation for the acceleration of the reaction, we examined the model reaction under ultrasonic irradiation at room temperature and with various amounts of catalyst. As shown in Table 1, the best results were obtained in the presence of 0.005 g of catalyst (Table 1, entry 15).

However, the synthesis of organic compounds under ultrasound irradiation is been limited by the need of a specialized apparatus that may not be available in many laboratories. Because of this limitation, herein we report both ultrasonic irradiation in the presence of 0.005 g of catalyst and also under solvent-free conditions in the presence of 0.015 g of catalyst at room temperature for the synthesis of α -aminophosphonates.

⁶ ACCEPTED MANUSCRIPT

Due to the above observations, a range of various aldehydes and amines was investigated to determine the method's scope and limitations. The results are summarized in Table 2. Aromatic aldehydes substituted with either electron-withdrawing or electron-donating groups underwent the reaction smoothly and gave the products in excellent yields, whereas aliphatic aldehydes afforded phosphonates in good yields, which is expected that aromatic aldehydes have higher reactivity than aliphatic aldehydes. In conclusion, aldehydes bearing electron-withdrawing groups required shorter times and gave higher yields (Table 2). The reactivity of heterocyclic aldehydes such as furan-2-carbaldehyde and thiophene-2-carbaldehyde with aromatic amines produced the corresponding products in excellent yields (Table 2, entries 20, 21). Moreover, in all of the above cases, ultrasonic irradiation gave comparable yields of products but within shorter reaction times, compared to solvent-free conditions at room temperature.

To demonstrate the value of the present work in comparison with some of the reported catalysts in the literature, the data on the reaction between benzaldehyde, aniline and triethyl phosphite are summarized in Table 3. This study showed that $Fe_3O_4@SiO_2$ -imid-PMAⁿ performs its catalytic role in a shorter reaction time and gives a higher yield of the desired product under solvent-free conditions and ultrasonic irradiation at room temperature (Table 3, entry 10). Moreover, some of the catalysts listed in Table 3 are not reusable and thus our reusable catalyst and methodologies represent a better alternative compared to the reported methods for the production of the corresponding products.

The magnetic separability of the prepared magnetic catalyst was tested in ethyl acetate solution by placing a magnet beside the glass cylinder. As displayed in Fig. 2a, without an outer magnet, $Fe_3O_4@SiO_2$ -imid-PMAⁿ prepared could be well dispersed in ethyl acetate solution to form a

⁷ ACCEPTED MANUSCRIPT

suspension. With the aid of an external magnetic field, the nanoparticles were attracted to the magnet and separated easily from the solution, which suggest that the catalyst possesses good separability and magnetism.

The recovery and reusability of the catalyst were examined in the synthesis of α aminophosphonates (Fig 2b). After the separation of products, the catalyst was washed with ethanol, dried and stored for another consecutive reaction run. The activity of the catalyst did not get much affected in terms of yields after six successive runs for the model reaction. It revealed that the catalyst displayed very good reusability.

SEM and DLS images of the catalyst after the sixth synthesis cycle of α -aminophosphonate (**1a**) under solvent-free conditions at room temperature are shown in Fig. 2c,d. The SEM image shows that the nanoparticles exhibit approximately spherical shapes. Additionally, the hydrodynamic diameter of catalyst was investigated by use of the DLS technique. As shown in Fig. 2d, a narrow size distribution of Fe₃O₄@SiO₂-imid-PMAⁿ NPs was obtained with a mean diameter of around 65 nm. Generally, the size of catalysts will be increased after each cycle and leaching of H₃PMo₁₂O₄₀ and the increase of the catalyst size leads to decreases in the yield.

2. Experimental

2.1. Materials and physical measurements

All chemicals were purchased from Merck, Fluka or Acros Chemical Companies in high purity and used without any further purification. The ¹H NMR and ¹³C NMR spectra were recorded on a Bruker Avance DPX 250 MHz Spectrometer in CDCl₃ solvent using TMS as an internal standard reference. Fourier transform infrared spectroscopy (FT-IR) analysis of the samples was taken on a Shimadzu FT-IR 8300 spectrophotometer and the sample and KBr were pressed to

⁸ ACCEPTED MANUSCRIPT

form a tablet. Scanning electron microscopy (SEM) image was obtained on Philips XL-30ESEM. Dynamic light scatterings (DLS) were recorded on a HORIBALB550. Sonication was performed using an ultrasound cleaning bath (KQ-250B, China) with a frequency of 30 Hz and voltage of 220 V. Melting points were determined with a Buchi 510 instrument in open capillary tubes and are uncorrected. Determination of the purity of the substrate and monitoring of the reaction were accomplished by thin layer chromatography (TLC) on a silica gel polygram SILG/UV 254 plates. All products were identified by comparison of their spectral data and physical properties with those of the authentic sample and all yields refer to isolated products. The Supplemental Materials contains characterization data and sample ¹H and ¹³C NMR spectra (Figures S 1 -- S 8).

2.2. General procedure

2.2.1. Preparation of Fe₃O₄@SiO₂-imid-PMAⁿ

Fe₃O₄@SiO₂-imid-PMAⁿ nanoparticles were prepared in our previous work.^[59-64]

2.2.2. General procedure for synthesis of α-aminophosphonates

To a mixture of aldehyde (1 mmol), amine (1 mmol) and triethyl phosphite (1.2 mmol) was added $Fe_3O_4@SiO_2$ -Imid-PMAⁿ (0.015 g or 0.005 g), and the mixture was stirred under solvent-free conditions or sonicated at room temperature for a particular period of time as given in Table 2. The progress of the reaction was monitored by TLC (eluent: EtOAc/*n*-hexane, 30:70). After the reaction was complete, EtOAc (2×5 mL) was added to the reaction mixture and the catalyst was separated by magnetic field. The filtrate was dried and the organic medium was removed with a rotary evaporator under reduced pressure. The residue was purified by silica gel column

⁹ ACCEPTED MANUSCRIPT

chromatography eluting with *n*-hexane-ethyl acetate (7:3) to afford the corresponding pure α -aminophosphonate.

4. Conclusion

In conclusion, the present communication reports an efficient green synthesis of α aminophosphonates in excellent yield with short reaction times via one-pot three-component reaction in the presence of Fe₃O₄@SiO₂-imid-PMAⁿ nanoparticles under solvent free or ultrasound conditions at room temperature. Short reaction time achieved by ultrasonication is an additional advantage of this reaction. This method provides notable advantages such as easy preparation, easy separation, thermal stability, and heterogeneous nature of the catalyst, easy product separation and purification, solvent-free conditions, excellent yields of desired products, short reaction times, lower loading of catalyst compared with the other methods and hence environmentally benign methodology that makes this method a useful and attractive process for the synthesis of these important compounds. In addition, the catalyst was recycled and reused six times by using an external permanent magnet without considerable loss of catalytic activity.

Selected spectral data

Diethyl (phenyl)(phenylamino)methanephosphonate (1a)

White solid, M.P. = 85-86°C (lit. 86°C);^{[32,65] 1}H NMR (250 MHz, CDCl₃) δ : 1.05 (t, 3H, $J_{H,H}$ = 7.1 Hz, OCH₂<u>CH₃</u>), 1.28 (t, 3H, $J_{H,H}$ = 7.1 Hz, OCH₂<u>CH₃</u>), 3.60-3.67 (m, 1H, OC<u>H₂</u>CH₃), 3.90-3.92 (m, 1H, O<u>CH₂</u>CH₃), 4.05-4.14 (m, 2H, O<u>CH₂</u>CH₃), 4.74 (d, 1H, ² $J_{P,H}$ = 26.4 Hz, CHP), 4.82 (br s, 1H, NH), 6.57-6.69 (m, 3H, ArH), 7.04 (t, 2H, $J_{H,H}$ = 7.2 Hz, ArH), 7.22-7.33 (m, 3H, ArH), 7.45-7.47 (d, 2H, $J_{H,H}$ = 7.2 Hz, ArH) ppm; ¹³C NMR (62.9 MHz, CDCl₃) δ : 16.1 (d, ³ $J_{C,P}$ = 6.2 Hz, OCH₂<u>CH₃</u>), 16.3 (d, ³ $J_{C,P}$ = 6.2 Hz, OCH₂<u>CH₃</u>), 54.8 (d, ¹ $J_{C,P}$ = 150.0 Hz, CP), 63.2 (d,

¹⁰ ACCEPTED MANUSCRIPT

²*J*_{*C,P*} = 6.5 Hz, O<u>CH</u>₂CH₃), 63.3 (d, ²*J*_{*C,P*} = 6.5 Hz, O<u>CH</u>₂CH₃), 113.8, 118.3, 127.8, 127.8, 128.5, 128.5, 129.1, 135.9, 146.2, 146.4 (ArH) ppm; ³¹P NMR (120 MHz, CDCl₃): δ = 21.066 ppm; MS (70 eV), m/e: 319 (M⁺), 182 [M-P(O)(OEt)₂]. Anal. Calcd for C₁₇H₂₂NO₃P: C, 63.95; H, 6.89; N, 4.39; Found: C, 63.88; H, 6.99; N, 4.30%.

Diethyl (phenyl)-N-(4-methylphenylamino)methanephosphonate (1b)

White solid; M.p. = 116 °C (lit.117-118 °C);^[33] ¹H NMR (250 MHz, CDCl₃) δ : 1.15 (t, 3H, $J_{H,H}$ = 7.0 Hz, OCH₂<u>CH₃</u>), 1.31 (t, 3H, $J_{H,H}$ = 7.0 Hz, OCH₂<u>CH₃</u>), 2.21 (s, 3H, CH₃), 3.70-3.76 (m, 1H, O<u>CH₂</u>CH₃), 3.92-4.02 (m, 1H, O<u>CH₂</u>CH₃), 4.11-4.20 (m, 2H, O<u>CH₂</u>CH₃), 4.72-4.82 (m, 2H, CH, NH), 6.55 (d, 2H, $J_{H,H}$ = 8.2 Hz, ArH), 6.94 (d, 2H, $J_{H,H}$ = 8.1 Hz, ArH), 7.29-7.38 (m, 3H, ArH), 7.48-7.51 (m, 2H, ArH) ppm; ¹³C NMR (62.9 MHz, CDCl₃) δ : 16.6 (d, ³ $J_{C,P}$ = 5.8 Hz, OCH₂<u>CH₃</u>), 16.8 (d, ³ $J_{C,P}$ = 5.8 Hz, OCH₂<u>CH₃</u>), 20.76 (CH₃), 56.7 (d, ¹ $J_{C,P}$ = 150.4 Hz, CH), 63.6-63.7 (O<u>CH₂</u>CH₃), 114.4, 128.0-130.1, 136.4, 144.2-144.5 (ArH) ppm; MS (70 eV), m/e: 333 (M⁺), 196 [M – diethyl(phenyl)-*N*-(phenyl)aminomethanephosphonate P(O)(OEt)₂]; Anal. Calcd for C₁₈H₂₄NO₃P: C, 64.85; H, 7.26; N, 4.20; Found: C, 64.79; H, 7.21; N, 4.13%.

Diethyl (4-hydroxyphenyl)(phenylamino)methanephosphonate (1e)

Viscous colorless oil;^{[32] 1}H NMR (250 MHz, CDCl₃) δ : 0.89 (t, 3H, ²*J*_{*H*,*H*} = 7.1 Hz, OCH₂C<u>H</u>₃), 1.04-1.12 (t, 3H, *J*_{*H*,*H*} = 7.1 Hz, OCH₂C<u>H</u>₃), 3.48-3.54 (m, 1H, OC<u>H</u>₂CH₃), 3.70-3.76 (m, 1H, OC<u>H</u>₂CH₃), 3.84-3.91 (m, 2H, OC<u>H</u>₂CH₃), 4.55 (d, 1H, ²*J*_{*P*,*H*} = 23.6 Hz, CHP), 4.96 (s, 1H, PhOH), 5.45 (br s, 1H, NH), 6.40-6.50 (m, 3H, ArH), 6.64 (d, 2H, *J*_{*H*,*H*} = 6.5 Hz, ArH), 6.86 (d, 2H, *J*_{*H*,*H*} = 7.1 Hz, ArH), 7.08 (d, 2H, *J*_{*H*,*H*} = 6.5 Hz, ArH) ppm; ³¹P NMR (120 MHz, CDCl₃): δ = 21.29 ppm; Anal. calcd for C₁₇H₂₂NO₄P: C, 60.89; H, 6.61; N, 4.18; Found: C, 60.77; H, 6.54; N, 4.09%.

¹¹ ACCEPTED MANUSCRIPT

Diethyl (4-methoxyphenyl)(phenylamino)methanephosphonate (1f)

Viscous colorless oil;^[52,65] ¹H NMR (250 MHz, CDCl₃) δ : 1.10, (t, 3H, $J_{H,H} = 7.0$ Hz, OCH₂CH₃), 1.24, (t, 3H, $J_{H,H} = 7.1$ Hz, OCH₂CH₃), 3.75 (s, 3H, OCH₃), 3.67-3.71, (m, 1H, OCH₂CH₃), 3.89-3.96, (m, 1H, OCH₂CH₃), 4.06-4.14, (m, 2H, OCH₂CH₃), 4.67-4.76 (m, 2H, CHP, NH), 6.57-6.70 (m, 3H, ArH), 6.83 (d, 2H, $J_{H,H} = 10.0$ Hz, ArH), 7.06 (t, 2H, $J_{H,H} = 7.5$, ArH), 7.35-7.40 (m, 2H, ArH) ppm; ¹³C NMR (62.9 MHz, CDCl₃) δ : 16.2 (d, ³ $J_{C,P} = 5.6$ Hz, OCH₂CH₃), 16.4 (d, ³ $J_{C,P} = 5.6$ Hz, OCH₂CH₃), 54.1 (d, ¹ $J_{C,P} = 150.0$ Hz, CP), 55.2 (OCH₃), 63.2 (d, ² $J_{C,P} = 6.5$ Hz, OCH₂CH₃), 113.9, 114.1, 118.3, 127.6, 128.9, 129,0, 129.1, 146.2, 146.5, 159.3 (ArH) ppm; IR (KBr, Cm⁻¹): 3292 (NH), 1231 (P = O), 1049 (P-OEt); ³¹P NMR (120 MHz, CDCl₃): $\delta = 21.284$ ppm; MS (70 eV), m/e: 349 (M⁺), 212 [M-P(O)(OEt)₂]; Anal. Calcd for C₁₈H₂₄NO₄P: C, 61.88; H, 6.92; N, 4.01; Found: C, 61.79; H, 6.98; N, 3.94%.

Diethyl(4-methoxyphenyl)(4-methoxyphenylamino)methanephosphonate (1h)

White solid, M.p. = 120-121°C (lit. 118°C);^{[32] 1}H NMR (250 MHz, CDCl₃) δ : 1.09 (t, 3H, $J_{H,H}$ = 7.0 Hz, OCH₂CH₃), 1.27 (t, 3H, $J_{H,H}$ = 7.0 Hz, OCH₂CH₃), 3.40 (s, 6H, O<u>CH₃</u>), 3.62-3.70 (m, 1H, O<u>CH₂CH₃</u>), 3.87-3.92 (m,1H, O<u>CH₂CH₃</u>), 4.03-4.12 (m, 2H, O<u>CH₂CH₃</u>), 4.62 (d,1H, ² $J_{P,H}$ = 24.2 Hz, CHP), 5.45 (br s, 1H, -NH), 6.51 (d, 2H, $J_{H,H}$ = 7.5 Hz, ArH), 6.67 (d, 2H, $J_{H,H}$ = 7.2 Hz, ArH), 6.96 (d, 2H, $J_{H,H}$ = 8.5 Hz, ArH), 7.20 (d, 2H, $J_{H,H}$ = 8.5 Hz, ArH) ppm; ³¹P NMR (120 MHz, CDCl₃) δ = 22.3 ppm; MS (70 eV), m/e: 379, 253, 241, 226, 171, 184, 128, 92, 77; Anal. Calcd for C₁₉H₂₆NO₅P: C, 60.16; H, 6.86; N, 3.69; Found: C, 60.05; H, 6.76; N, 3.61%.

Diethyl (4-methoxyphenyl) (4-nitrophenyl amino)methanephosphonate (1i)

Yellow solid, M.p. = 114-115°C (lit. 115°C);^{[66] 1}H NMR (250 MHz, CDCl₃) δ : 0.89 (t, 3H, J_{HH} = 7.1 Hz, OCH₂CH₃), 0.97 (t, 3H, J_{HH} = 7.1 Hz, OCH₂CH₃), 3.42 (s, 3H, PhOMe), 3.81-3.90 (m,

¹² ACCEPTED MANUSCRIPT

4H, O<u>CH₂</u>CH₃), 4.55 (d, 1H, ${}^{2}J_{HP}$ = 23.7 Hz, CHP), 6.38 (d, 2H, $J_{H,H}$ = 9.1 Hz, ArH), 6.55 (d, 2H, $J_{H,H}$ = 8.5 Hz, ArH), 6.65 (br s, 1H, NH), 7.13 (dd, 2H, $J_{H,H}$ = 8.5, 2.1 Hz, ArH), 7.96 (d, 2H, $J_{H,H}$ = 9.1 Hz, ArH); 31 P NMR (120 MHz, CDCl₃) δ = 22.2 ppm; Anal. Calcd for C₁₈H₂₃N₂O₆P: C, 54.82; H, 5.88; N, 7.10; Found: C, 54.78; H, 5.83; N, 7.06%.

Diethyl (phenylamino)(p-tolyl)methanephosphonate (11)

White solid, M.p. = 61-62°C (lit. 60°C);^{[32] 1}H NMR (250 MHz, CDCl₃) δ : 0.97 (t, 3H, $J_{H,H}$ = 7.0 Hz, OCH₂CH₃), 1.10 (t, 3H, $J_{H,H}$ = 7.0 Hz, OCH₂CH₃), 2.12 (s, 3H, Ph<u>CH₃</u>), 3.52-3.55 (m, 1H, O<u>CH₂CH₃</u>), 3.73-3.80 (m, 1H, O<u>CH₂CH₃</u>), 3.92-4.00 (m, 2H, O<u>CH₂CH₃</u>), 4.61 (d, 1H, ² $J_{P,H}$ = 24.1 Hz, CHP), 4.97 (br s, 1H, NH), 6.44-6.53 (m, 3H, ArH), 6.79-7.02 (m, 4H, ArH), 7.22 (d, 2H, ArH) ppm; ³¹P NMR (120 MHz, CDCl₃) δ = 19.89 ppm; Anal. Calcd for C₁₈H₂₄NO₃P: C, 64.85; H, 7.26; N, 4.20; Found: C, 64.78; H, 7.21; N, 4.16%.

Diethyl (4-chlorophenyl)(phenylamino)methanephosphonate (1m)

White solid, M.p. = 55-57°C (lit. 57°C);^{[32] 1}H NMR (250 MHz, CDCl₃) δ : 1.12 (t, 3H, $J_{H,H}$ = 7.1 Hz, OCH₂CH₃), 1.25 (t, 3H, $J_{H,H}$ = 7.1 Hz, OCH₂CH₃), 3.69-3.79 (m, 1H, OCH₂CH₃), 3.96-4.0 (m, 1H, OCH₂CH₃), 4.09-4.15 (m, 2H, OCH₂CH₃), 4.60-4.77 (m, 2H, CHP, NH), 6.54 (d, 2H, $J_{H,H}$ = 7.8 Hz, ArH), 6.57 (t, 1H, $J_{H,H}$ = 7.3 Hz, ArH), 7.03 (t, 2H, $J_{H,H}$ = 7.8 Hz, ArH), 7.28-7.32 (m, 2H, ArH), 7.39-7.43 (m, 2H, ArH) ppm; ¹³CNMR (62.9 MHz, CDCl₃) δ : 16.2 (d, ³ $J_{C,P}$ = 5.6 Hz, OCH₂CH₃), 16.4 (d, ³ $J_{C,P}$ = 5.6 Hz, OCH₂CH₃), 54.3 (d, ¹ $J_{C,P}$ = 150, CP), 63.3 (d, ² $J_{C,P}$ = 6.5 Hz, OCH₂CH₃), 113.8, 118.6, 128.8, 129.1, 129.2, 129.2, 133,7, 134.6, 145.8, 146.1 (ArH) ppm; ³¹P NMR (120 MHz, CDCl₃) δ = 20.00 ppm; MS (70 eV), m/e: 353 (M⁺), 355 (M⁺²), 216 [M-P(O)(OEt)₂]; Anal. Calcd for C₁₇H₂₁ClNO₃P: C, 57.72; H, 5.98; N, 3.96; Found: C, 57.64; H, 5.91; N, 3.88%.

¹³ ACCEPTED MANUSCRIPT

Diethyl (2-chlorophenyl)(phenylamino)methanephosphonate (1n)

White solid, M.p. = 89 °C (lit. 88-90°C);^{[66] 1}H NMR (250 MHz, CDCl₃) δ : 0.95 (t, 3H, $J_{H,H}$ = 7.0 Hz, OCH₂CH₃), 1.20 (t, 3H, $J_{H,H}$ = 6.9 Hz, OCH₂CH₃), 3.53-3.56 (m,1H, O<u>CH₂CH₃</u>), 3.75-3.82 (m, 1H, O<u>CH₂CH₃</u>), 4.09- 4.15 (m, 2H, O<u>CH₂CH₃</u>), 5.33 (d, 1H, ² $J_{H,P}$ = 24.8 Hz, CHP), 6.4 (br s, 1H, NH), 6.56 (d, 2H, $J_{H,H}$ = 7.8 Hz, ArH), 6.58 (t, 1H, $J_{H,H}$ = 7.2 Hz, ArH), 6.95-7.10 (m, 6H, ArH); ³¹P (120 MHz, CDCl₃): δ = 20.01 ppm; Anal. Calcd for C₁₇H₂₁ClNO₃P: C, 57.72; H, 5.98; N, 3.96; Found: C, 57.65; H, 5.91; N, 3.89%.

Diethyl (4-bromophenyl)(phenylamino)methanephosphonate (10)

White solid; M.p. = 66-67 °C (lit. 66-68°C);^{[59] 1}H NMR (250 MHz, CDCl₃) δ : 1.17 (t, 3H, $J_{H,H}$ = 8.75 Hz, OCH₂CH₃), 1.28 (t, 3H, $J_{H,H}$ = 8.75 Hz, OCH₂CH₃), 3.69-3.79 (m, 1H, OCH₂CH₃), 4.09-4.13 (m, 3H, OCH₂CH₃), 4.66-4.76 (m, 2H, CHP, NH), 6.53-6.57 (m, 3H, ArH), 7.10 (t, 2H, $J_{H,H}$ = 7.5 Hz, ArH), 7.33-7.76 (m, 4H, ArH) ppm; ¹³CNMR (62.9 MHz, CDCl₃) δ : 16.2 (d, ${}^{3}J_{C,P}$ = 5.6 Hz, OCH₂CH₃), 16.4 (d, ${}^{3}J_{C,P}$ = 5.6 Hz, OCH₂CH₃), 54.4 (d, ${}^{1}J_{C,P}$ = 150, CP), 63.2 (d, ${}^{2}J_{C,P}$ = 6.5 Hz, OCH₂CH₃), 63.4 (d, ${}^{2}J_{C,P}$ = 6.5 Hz, OCH₂CH₃), 113.8, 118.6, 121.8, 121.9, 129.2, 129.4, 129.5, 131.7, 131.8, 135.1, 145.8, 146.1 (ArH) ppm; ³¹P NMR (120 MHz, CDCl₃): δ = 20.197 ppm; MS (70 eV), m/e: 399, 397 (M⁺); Anal. Calcd for C₁₇H₂₁BrNO₃P: C, 51.27; H, 5.28; N, 3.52; Found: C, 57.18; H, 5.21; N, 3.43%.

Diethyl (4-nitrophenyl)(phenylamino)methanephosphonate (1q)

Bright yellow solid, M.p. = $121-122^{\circ}C$ (lit. $120^{\circ}C$);^{[32] 1}H NMR (250 MHz, CDCl₃) δ : 1.16 (t, 3H, $J_{H,H} = 6.9$ Hz, OCH₂CH₃), 1.26 (t, 3H, $J_{H,H} = 6.9$ Hz, OCH₂CH₃), 3.86-4.17 (m, 4H, OCH₂CH₃), 4.90 (d, 1H, ${}^{2}J_{P,H} = 25.2$ Hz, CHP), 5.21 (br s, 1H, NH), 6.55 (d, 2H, $J_{H,H} = 7.7$ Hz, ArH), 6.67 (t, 1H, $J_{H,H} = 7.1$ Hz, ArH), 7.06 (t, 2H, $J_{H,H} = 7.1$ Hz, ArH), 7.66 (dd, 2H, $J_{H,H} = 8.5$,

¹⁴ ACCEPTED MANUSCRIPT

2.2 Hz, ArH), 8.13 (d, 2H, $J_{H,H}$ = 8.5 Hz, ArH) ppm; IR (KBr, cm⁻¹): 3287 (NH), 1232 (P = O), 1054 (P-OEt); ³¹P (120 MHz, CDCl₃): δ = 21.4 ppm; MS (70 eV), m/e: 364.12 (M⁺), 226; Anal. Calcd for C₁₇H₂₁N₂O₅P: C, 56.04; H, 5.81; N, 7.69; Found: C, 55.91; H, 5.73; N, 7.52%.

Diethyl (3-nitrophenyl)(phenylamino)methanephosphonate (1s)

Yellow crystalline solid, M.p. = 97-98°C(lit. 95-97°C);^[33] ¹H NMR (250 MHz, CDCl₃) δ : 1.09 (t, 3H, $J_{H,H} = 7.0$ Hz, OCH₂CH₃), 3.73-4.15 (m, 4H, O<u>CH₂CH₃</u>), 4.82 (d, 1H, ${}^{2}J_{P,H} = 24.8$ Hz, CHP), 5.46 (br s, 1H, NH), 6.48-6.65 (m, 3H, ArH), 7.01 (t, 2H, $J_{H,H} = 7.8$ Hz, ArH), 7.40 (t, 1H, $J_{H,H} = 7.5$ Hz, ArH), 7.76 (d, 1H, $J_{H,H} = 7.7$ Hz, ArH), 8.05 (d, 1H, $J_{H,H} = 9.5$ Hz, ArH), 8.29 (s, 1H, ArH) ppm; ¹³C NMR (62.9 MHz,CDCl₃) δ : 16.2 (d, ${}^{3}J_{C,P} = 5.6$ Hz, OCH₂CH₃), 16.4 (d, ${}^{3}J_{C,P} = 5.6$ Hz, OCH₂CH₃), 56.7 (d, ${}^{1}J_{C,P} = 150.1$ Hz, CP), 63.4 (d, ${}^{2}J_{C,P} = 6.9$ Hz, OCH₂CH₃), 63.8 (d, ${}^{2}J_{C,P} = 6.9$ Hz, OCH₂CH₃), 113.7, 118.8, 122.8, 122.9, 129.2, 133.8, 133.9, 138.8, 138.9, 145.6, 145.8, 148.4 (ArH) ppm; Anal. Calcd for C₁₇H₂₁N₂O₅P: C, 56.04; H, 5.81; N, 7.69; Found: C, 55.95; H, 5.71; N, 7.55%.

Diethyl (phenylamino)(thiophen-2-yl)methanephosphonate (1u)

White solid, M.p. = 68-69°C (lit. 70°C);^{[32] 1}H NMR (250 MHz, CDCl₃) δ : 0.78 (t, 3H, $J_{H,H}$ = 7.1 Hz, OCH₂CH₃), 1.10 (t, 3H, $J_{H,H}$ = 7.1 Hz, OCH₂CH₃), 3.82-4.11 (m, 4H, OCH₂CH₃), 4.5 (1H, NH), 4.97 (d, 1H, ${}^{2}J_{P,H}$ = 23.65 Hz, CHP), 6.68-6.70 (m, 3H, ArH), 6.89-6.91 (m, 1H, ArH), 7.04-7.15 (m, 4H, ArH) ppm; 13 C NMR (62.9 MHz, CDCl₃) δ : 16.3 (d, ${}^{3}J_{C,P}$ = 5.8 Hz, OCH₂CH₃), 16.4 (d, ${}^{3}J_{C,P}$ = 5.8 Hz, OCH₂CH₃), 52.1 (d, ${}^{1}J_{C,P}$ = 158.2 Hz, CP), 63.4 (d, ${}^{2}J_{C,P}$ = 7.0 Hz, OCH₂CH₃), 63.6 (d, ${}^{2}J_{C,P}$ = 7.0 Hz, OCH₂CH₃), 114.0, 118.9, 124.0, 125.2, 126.1, 127.1, 129.2, 139.9, 146.1 (ArH) ppm; MS (70 eV): m/e = 325 [M⁺], 188 [M-P(O)(OEt)₂]; Anal. Calcd for C₁₅H₂₀NO₃PS: C, 55.37; H, 6.20; N, 4.31; Found: C, 55.30; H, 6.13; N, 4.26%.

¹⁵ ACCEPTED MANUSCRIPT

Diethyl (n-propyl)-N-(phenyl)aminomethanephosphonate (1w)

Viscous colourless oil;^[52] ¹H NMR (250 MHz, CDCl₃) δ : 0.84 (t, 3H, $J_{H,H}$ = 7.2 Hz, CH₃), 1.09-1.24 (m, 6H, OCH₂<u>CH₃</u>), 1.50-1.82 (m, 4H, (<u>CH₂</u>)₂CH₃), 3.60-3.65 (m, 2H, NH, CHP), 3.94-4.09 (m, 4H, O<u>CH₂</u>CH₃), 6.58 (d, 2H, $J_{H,H}$ = 8.2 Hz, ArH), 6.65 (d, 1H, $J_{H,H}$ = 7.4 Hz, ArH), 7.09 (t, 2H, $J_{H,H}$ = 7.6 Hz, ArH) ppm; MS (70 eV), m/e: 285 (M⁺), 148 [M-P(O)(OEt)₂]; Anal. Calcd for C₁₄H₂₄NO₃P: C, 58.93; H, 8.48; N, 4.91; Found: C, 58.85; H, 8.41; N, 4.84%.

Acknowledgements

Authors are grateful to the council of Iran National Science Foundation and University of Shiraz for their unending effort to provide financial support to undertake this work.

¹⁶ ACCEPTED MANUSCRIPT

References

- [1] Kleszczynska, H.; Sarapuk, J. Cell. Biol. Mol. Lett. 2001, 6, 83-91.
- [2] Allen, M. C.; Fuhrer, W.; Tuck, B.; Wade, R.; Wood, J. M. J. Med. Chem. 1989, 32, 1652-1661.
- [3] Atherton, F. R.; Hassall, C. H.; Lambert, R. W. J. Med. Chem. 1986, 29, 29-40.
- [4] Atherton, F. R.; Hassall, C. H.; Lambert, R. W. J. Med. Chem. 1987, 30, 1603-1609.
- [5] Rozenfeld, R.; Iturrioz, X.; Okada, M.; Maigret, B.; Llorens-Cortes, C. *Biochemistry* 2003, 42, 14785-14793.
- [6] Dillard, R. D.; Pavey, D. E.; Benslay, D. N. J. Med. Chem. 1973, 16, 251-253.
- [7] Hirschmann, R.; Smith, A. B.; Taylor, C. M.; Benkovic, P. A.; Taylor, S. D.; Yager, K. M.;
 Sprengler, P. A.; Venkovic, S. J. *Science* 1994, 265, 234-237.
- [8] Maier, L. Phosphorus Sulfur Silicon Relat Elem. 1990, 53, 43-55.
- [9] Lombaert, S. D.; Blanchard, L.; Tan, J.; Sakane, Y.; Berry, C.; Ghai, R. D. Bioorg. Med. Chem. Lett. 1995, 5, 145-150.
- [10] Danila, C. D.; Wang, X.; Hubble, H.; Antipin, I. S.; Pinkhassik, E. *Bioorg. Med. Chem. Lett.* **2008**, 18, 2320-2323.
- [11] Peyman, A.; Stahl, W.; Wagner, K.; Ruppert, D.; Budt, K. H. *Bioorg. Med. Chem. Lett.* 1994, 4, 2601-2604.
- [12] Miller, D. J.; Hammond, S. M.; Anderluzzi, D.; Bugg, T. D. H. J. Chem. Soc. Perkin. Trans.1998, 1, 131-142.
- [13] Maier, L.; Spoerri, H. Phosphorus Sulfur Silicon Relat Elem. 1991, 61, 69-75.

¹⁷ ACCEPTED MANUSCRIPT

- [14] Kleszczynska, H.; Bonarska, D.; Bielecki, K.; Sarapuk, J. Cell. Mol. Biol. Lett. 2002, 7, 929-935.
- [15] Emsley, J.; Hall, D. The Chemistry of Phosphorus, Harper & Row, London, 1976.
- [16] Song, B. A.; Wu, Y. L.; Yang, S.; Hu, D. Y.; He, X. Q.; Jin, L. H. *Molecules* 2003, 8, 186-192.
- [17] Sal'keeva, L. K.; Nurmaganbetova, M. T.; Kurmanaliev, O. S.; Gazizov, T. K. Russ. J. Org. Chem. 2002, 38, 723-725.
- [18] Bhattacharya, A. K.; Rana, K. C. Tetrahedron Lett. 2008, 49, 2598-2601.
- [19] Mitragotri, S. D.; Pore, D. M.; Desai, U. V.; Wadgaonkar, P. P. Catal. Commun. 2008, 9, 1822-1826.
- [20] Kaboudin, B.; Jafari, E. J. Iran. Chem. Soc. 2008, 5, S97-S102.
- [21] Akiyama, T.; Sanada, M.; Fuchibe, K. Synlett 2003, 1463-1464.
- [22] Vahdat, S. M.; Baharfar, R.; Tajbakhsh, M.; Heydari, A.; Baghbanian, S. M.; Haksar, S. *Tetrahedron Lett.* 2008, 49, 6501-6504.
- [23] Maghsoodlou, M. T.; Habibi-Khorassani, S. M.; Heydari, R.; Hazeri, N.; Sajadikhah, S. S.;Rostamizadeh, M. *Chin. J. Chem.* 2010, 28, 285-288.
- [24] Elmakssoudi, A.; Zahouily, M.; Mezdar, A.; Rayadh, A.; Sebti, S. *Comt. Rend. Chimie.*2005, 8, 1954-1959.
- [25] Azizi, N.; Rajabi, F.; Saidi, M. R. Tetrahedron Lett. 2004, 45, 9233-9236.
- [26] Kumar, A. S.; Taneja, S. C.; Hundal, M. S.; Kapoor, K. K. *Tetrahedron Lett.* 2008, 49, 2208-2212.
- [27] Ranu, B. C.; Hajra, A.; Jana, U. Org. Lett. 1999, 1, 1141-1143.

¹⁸ ACCEPTED MANUSCRIPT

- [28] Zhan, Z. P.; Li, J. P. Synth. Commun. 2005, 35, 2501-2508.
- [29] Manjula, A.; Rao, B. V.; Neelakantan, P. Synth. Commun. 2003, 33, 2963-2969.
- [30] Rezaei, Z.; Firouzabadi, H.; Iranpoor, N.; Ghaderi, A.; Jafari, M. R.; Jafari, A. A.; Zare, H.
 R. *Eur. J. Med. Chem.* 2009, 44, 4266-4275.
- [31] Chandrasekhar, S.; Prakash, S. J.; Jagadeshwar, V.; Narsihmulu, C. *Tetrahedron Lett.* 2001, 42, 5561-5563.
- [32] Hosseini-Sarvari, M. Tetrahedron 2008, 64, 5459-5466.
- [33] Tang, J.; Wang, L.; Wang, W.; Zhang, L.; Wu, S.; Mao, D. J. Fluor. Chem. 2011, 132, 102-106.
- [34] Kudrimoti, S.; Bommena, R. V. Tetrahedron Lett. 2005, 46, 1209-1210.
- [35] Heydari, A.; Arefi, A. Catal. Commun. 2007, 8, 1023-1026.
- [36] Bruce, I. J.; Sen, T. Langmuir 2005, 21, 7029-7035.
- [37] Esmaeilpour, M.; Javidi, J.; Nowroozi Dodeji, F.; Hassannezhad, H. J. Iran. Chem. Soc.2014, 11, 1703-1715.
- [38] Alexiou, C.; Jurgons, R.; Schmid, R.; Hilpert, A.; Bergemann, C.; Parak, F.; Iro, H. J. Magn. Magn. Mater. 2005, 293, 389-393.
- [39] Wong, E. W.; Bronikowski, M. J.; Hoenk, M. E.; Kowalczyk, R. S.; Hunt, B. D. Chem. Mater. 2005, 17, 237-241.
- [40] Esmaeilpour, M.; Javidi, J.; Mokhtari Abarghoui, M.; Nowroozi Dodeji, F. J. Iran. Chem. Soc. 2014, 11, 499-510.
- [41] Lei, Z.; Li, Y.; Wei, X. J. Solid. State . Chem. 2008, 181, 480-486.

¹⁹ ACCEPTED MANUSCRIPT

- [42] Esmaeilpour, M.; Javidi, J.; Dehghani, F.; Nowroozi Dodeji, F. New. J. Chem. 2014, 38, 5453-5461.
- [43] Dalaigh, C. O.; Corr, S. A.; Gunko, Y.; Connon, S. J. Angew. Chem. Int. Ed. 2007, 46, 4329-4332.
- [44] Schatz, A.; Hager, M.; Reiser, O. Adv. Funct. Mater. 2009, 19, 2109-2115.
- [45] Javidi, J.; Esmaeilpour, M.; Nowroozi Dodeji, F. RSC Adv. 2015, 5, 308-315.
- [46] Polshettiwar, V.; Luque, R.; Fihri, A.; Zhu, H.; Bouhrara, M.; Basset, J. M. *Chem. Rev.***2011**, 111, 3036-3075.
- [47] Esmaeilpour, M.; Javidi, J.; Zandi, M. Mater. Res. Bull. 2014, 55, 78-87.
- [48] Pourjavadi, A.; Hosseini, S. H.; Hosseini, S. T.; Aghayeemeibody, S. A. *Catal. Commun.***2012**, 28, 86-89.
- [49] Kumar, K. S.; Krishna, B. S.; Reddy, C. B.; Reddy, M. V. N.; Reddy, C. S. *Arab. J. Chem.* **2012**, in press, corrected proof available online, 3rd. October 2012.
- [50] Bhattacharya, A. K.; Raut, D. S.; Rana, K. C.; Polanki, I. K.; Khan, M. S.; Iram, S. Eur. J. Med. Chem. 2013, 66, 146-152.
- [51] Zhang, Y.; Zhu, C. Catal. Commun. 2012, 28, 134-137.
- [52] Sobhani, S.; Safaei, E.; Asadi, M.; Jalili, F. J. Organomet. Chem. 2008, 693, 3313-3317.
- [53] Hou, J. T.; Gao, J. W.; Zhang, Z. H. Appl. Organomet. Chem. 2011, 25, 47-53.
- [54] Hajinasiri, R.; Hossaini, Z.; Rostami-Charati, F. Heteroat. Chem. 2011, 22, 625-629.
- [55] Jafari, A. A.; Nazarpour, M.; Abdollahi-Alibeik, M. Heteroat. Chem. 2010, 21, 397-403.
- [56] Subba Reddy, B. V.; Siva Krishna, A.; Ganesh, A. V.; Narayana Kumar, G. G. K. S. *Tetrahedron Lett.* 2011, 52, 1359-1362.

²⁰ ACCEPTED MANUSCRIPT

- [57] Niralwad, K. S.; Shingate, B. B.; Shingare, M. S. Ultrason. Sonochem. 2010, 17, 760-763.
- [58] Agawane, S. M.; Nagarkar, J. M. Tetrahedron. Lett. 2011, 52, 3499-3504.
- [59] Javidi, J.; Esmaeilpour, M. Mater. Res. Bull. 2016, 73, 409-422.
- [60] Esmaeilpour, M.; Javidi, J. J. Chin. Chem. Soc. 2015, 62, 614-626.
- [61] Esmaeilpour, M.; Javidi, J. J. Chin. Chem. Soc. 2015, 62, 328-334.
- [62] Javidi, J.; Esmaeilpour, M.; Rajabnia Khansari, M. RSC Adv. 2015, 5, 73268-73278.
- [63] Esmaeilpour, M.; Javidi, J.; Dehghani, F.; Nowroozi Dodeji, F. *RSC Adv.* 2015, 5, 26625-26633.
- [64] Esmaeilpour, M.; Javidi, J.; Zandi, M. New. J. Chem. 2015, 39, 3388-3398.
- [65] Disale, S. T.; Kale, S. R.; Kahandal, S. S.; Srinivasan, T. G.; Jayaram, R. V. Tetrahedron Lett. 2012, 53, 2277-2279.
- [66] Xia, M.; Lu, Y. D. Ultrason. Sonochem. 2007, 14, 235-240.

²¹ ACCEPTED MANUSCRIPT

Table 1. Optimization of the amount of catalyst and solvent in a one-pot synthesis of the model

reaction.^a

Entry	Catalyst amount (g)	Solvent	Conditions	Time (min)	Yield (%) ^b
1	-	Solvent-Free	P(OEt) ₃	120	-
2	0.005	Solvent-Free	P(OEt) ₃	30	77
3	0.01	Solvent-Free	P(OEt) ₃	30	92
4	0.015	Solvent-Free	P(OEt) ₃	20	96
5	0.02	Solvent-Free	P(OEt) ₃	20	93
6	0.015	CH ₂ Cl ₂	P(OEt) ₃	20	86
7	0.015	CHCl ₃	P(OEt) ₃	30	81
8	0.015	CH ₃ CN	P(OEt) ₃	60	78
9	0.015	THF	P(OEt) ₃	60	73
10	0.015	Et ₂ O	P(OEt) ₃	60	67
11	0.015	C ₂ H ₅ OH	P(OEt) ₃	60	78
12	0.015	C ₂ H ₅ OH/H ₂ O	P(OEt) ₃	80	66
13	0.015	H ₂ O	P(OEt) ₃	80	64
14	0.015	Solvent-Free	HP(O)(OEt) ₂	70	82
15	0.005	Solvent-Free	Sonication (30	Δ	98
			kHz)/P(OEt) ₃		
16	0.01	Solvent-Free	Sonication (30	Δ	96
			kHz)/P(OEt) ₃		

^aReaction condition: benzaldehyde (1 mmol), aniline (1 mmol) and triethyl phosphate (1.2

mmol).

^bIsolated yield.

²² ACCEPTED MANUSCRIPT

Entry	R ₁	R ₂	Product	Solvent free/rt		Ultrasonic/Solvent free/rt		Ref.
				Time	Yield	Time	Yield (%) ^b	
				(min)	$(\%)^{b}$	(min)		
1	C ₆ H ₅	C ₆ H ₅	1a	20	96	2	98	[32]
2	C ₆ H ₅	<i>p</i> -MeC ₆ H ₄	1b	20	93	3	96	[33]
3	C ₆ H ₅	$p-NO_2C_6H_4$	1c	30	90	8	93	[48]
4	C ₆ H ₅	C ₆ H ₅ CH ₂	1d	20	92	5	95	[49]
5	<i>p</i> -HOC ₆ H ₄	C ₆ H ₅	1e	30	91	4	92	[32]
6	<i>p</i> -MeOC ₆ H ₄	C ₆ H ₅	1f	40	94	5	94	[32]
7	o-MeC ₆ H ₄	C ₆ H ₅	1g	40	92	7	95	[50]
8	<i>p</i> -MeOC ₆ H ₄	<i>p</i> -MeOC ₆ H ₄	1h	20	95	3	97	[32]
9	<i>p</i> -MeOC ₆ H ₄	$p-NO_2C_6H_4$	1i	60	92	9	94	[49]
10	<i>p</i> -MeC ₆ H ₄	<i>n</i> -Butyl	1j	20	93	3	92	[50]
11	<i>p</i> -MeC ₆ H ₄	<i>p</i> -MeC ₆ H ₄	1k	30	91	5	95	[51]
12	<i>p</i> -MeC ₆ H ₄	C ₆ H ₅	11	30	89	6	92	[32]
13	<i>p</i> -ClC ₆ H ₄	C ₆ H ₅	1m	15	95	2	97	[32]
14	o-ClC ₆ H ₄	C ₆ H ₅	1n	30	92	4	91	[32]
15	<i>p</i> -BrC ₆ H ₄	C ₆ H ₅	10	20	95	7	95	[51]
16	<i>p</i> -BrC ₆ H ₄	<i>p</i> -MeC ₆ H ₄	1p	15	95	4	97	[51]
17	<i>p</i> -NO ₂ C ₆ H ₄	C ₆ H ₅	1q	15	96	2	95	[32]
18	$p-NO_2C_6H_4$	$p-NO_2C_6H_4$	1r	30	88	6	91	[48]
19	$m-NO_2C_6H_4$	C ₆ H ₅	1s	20	94	2	96	[48]
20	Furfuryl	C ₆ H ₅	1t	40	86	8	91	[48]
21	2-Thiophene	C ₆ H ₅	1u	45	91	8	93	[32]
22	<i>n</i> -Propyl	<i>p</i> -MeOC ₆ H ₄	1w	45	76	12	85	[52]

Table 2. One-pot synthesis of α	-aminophosphonate catalyze	ed by Fe ₃ O ₄ @SiO ₂ -imid-PMA ⁿ . ^a
---------------------------------	----------------------------	--

²³ ACCEPTED MANUSCRIPT

^aReaction condition: aldehyde (1 mmol), amine (1 mmol), triethyl phosphite (1.2 mmol), $Fe_3O_4@SiO_2$ imid-PMAⁿ (0.015 g), solvent free, room temperature or ultrasonic irradiation (30 kHz), $Fe_3O_4@SiO_2$ -imid-PMAⁿ (0.005 g).

^bIsolated yield.

²⁴ ACCEPTED MANUSCRIPT

Table 3. Comparison of the catalytic activity of $Fe_3O_4@SiO_2$ -imid-PMAⁿ with the reported catalysts in the preparation of diethyl (phenyl)(phenylamino)methanephosphonate (**1a**).

Entry	Catalyst	Condition	Time	Yield	Ref.	
			(min)	$(\%)^{a}$		
1	NbCl ₅	Solvent-free/50°C	30	95	[53]	
2	TiO ₂	Solvent-free/50°C	3.5h	98	[32]	
3	Choline chloride $\cdot 2ZnCl_2$	Solvent-free/r.t	60	96	[54]	
4	MNP@DSO ₃ H	Solvent-free/rt	25min	91	[48]	
5	CeCl ₃ .7H ₂ O	Solvent-free/rt	5h	95	[55]	
6	Nano-Fe ₃ O ₄	Solvent-free/50°C	48	94	[56]	
7	[Cu(3,4-	$H_2O, 80^{\circ}C$	30	96	[52]	
	tmtppa)](MeSO ₄) ₄					
8	Sodium 1- hexanesulfonate	Solvent-free/rt	60	75		
		Ultrasonic/Solvent-	15	94	[57]	
		free/rt				
9	CeO ₂	Ultrasonic/Solvent-	5	99	[58]	
		free/rt				
		Solvent free/r.t	20	96	This	
10	Fe ₃ O ₄ @SiO ₂ -imid-PMA ⁿ	Ultrasonic/Solvent- free/rt	2	98	work	

^aIsolated yield

²⁵ ACCEPTED MANUSCRIPT



Fig 1. Process for the preparation and immobilization of $H_3PMo_{12}O_{40}$ nanoparticles (PMAⁿ) on imidazole functionalized Fe₃O₄@SiO₂ nanoparticles.

²⁶ ACCEPTED MANUSCRIPT



Fig 2. (a) Recyclability of $Fe_3O_4@SiO_2$ -Imid-PMAⁿ in the synthesis of 1a; (b) Photographs of the separation and re-dispersion processes of $Fe_3O_4@SiO_2$ -Imid-PMAⁿ without external magnetic field and with external magnetic field; (c) and (d) SEM and DLS images of $Fe_3O_4@SiO_2$ -imid-PMAⁿ nanoparticles after six reaction cycles.

²⁷ ACCEPTED MANUSCRIPT



Scheme 1. Fe₃O₄@SiO₂-imid-PMAⁿ catalyzed synthesis of α -aminophosphonates.

²⁸ ACCEPTED MANUSCRIPT